Abstract
AbstractThe rarity of WM limits the ability to perform large randomized clinical trials comparing treatment regimens. Prospective single-arm studies, however, have led to the development of effective therapies. The choice of treatment should consider patient-specific characteristics and anticipated toxicities, as well as patient and provider preference. Additionally, MYD88 and CXCR4 mutations are known to affect treatment response and progression-free survival (PFS).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
